Phase I clinical trials of this anti-CD20/anti-CD3 antibody, Glofitamab, showed that at high doses, nearly 50% of previously treated patients with aggressive NHL had complete recovery after treatment, and 81% of those remained disease free past 2 years following treatment (47). This evidence concerns the gene MS4A1 and non-Hodgkin lymphoma.